30-day mortality | 1-year mortality | |||||||
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | |
Age years | 1.014 (0.971–1.059) | 0.533 | 1.010 (0.970–1.053) | 0.621 | ||||
Female | 0.206 (0.013–3.282) | 0.263 | 0.206 (0.014–2.975) | 0.246 | ||||
BMI kg·m−2 | 0.915 (0.851–0.985) | 0.018 | 0.927 (0.876–0.988) | 0.017 | 0.959 (0.903–1.018) | 0.166 | ||
Smoking status | 0.338 (0.102–1.123) | 0.077 | 0.564 (0.215–1.478) | 0.244 | ||||
Cardiovascular comorbidity | 5.184 (2.092–12.846) | <0.001 | 2.705 (0.937–7.808) | 0.096 | 3.793 (1.447–9.941) | 0.007 | 2.123 (0.711–6.337) | 0.177 |
GOLD stage | 1.940 (1.222–3.080) | 0.005 | 0.970 (0.556–1.692) | 0.736 | 2.046 (1.308–3.200) | 0.002 | 1.445 (0.840–2.484) | 0.183 |
Clinical signs of severity# | 0.049 (0.000–5.35) | 0.777 | 0.049 (0.000–2.560) | 0.769 | ||||
PaO2/FIO2 mmHg | 0.991 (0.986–0.997) | <0.001 | 0.993 (0.987–0.999) | 0.009 | 0.997 (0.991–1.003) | 0.344 | ||
Serum uric acid levels mg·dL−1 | 1.449 (1.199–1.752) | 0.001 | 1.317 (1.011–1.736) | 0.044 | 1.405 (1.164–1.697) | <0.001 | 1.186 (0.925–1.521) | 0.179 |
Bold indicates statistical significance. HR: hazard ratio; BMI: body mass index; GOLD: Global Initiative for Chronic Obstructive Lung Disease; PaO2: arterial oxygen tension; FIO2: inspiratory oxygen fraction. #: includes the presence of haemodynamic instability, tachypnoea and/or the use of accessory respiratory muscles.